Table 3. Association of LINE-1 and Alu methylation with prevalence of baseline cancers.
| Methylation | Cancer-free | Cancer | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
||||||||||
| All | Prostate cancer | Lung cancer | Colorectal cancer | Other cancers | |||||||
|
|
|
|
|
|
|||||||
| n (%) | n (%) | OR (95% CI)a | n (%) | OR (95% CI)a | n (%) | OR (95% CI)a | n (%) | OR (95% CI)a | n (%) | OR (95% CI)a | |
| LINE-1 (%5mC) | |||||||||||
| Quartileb | |||||||||||
| Q4 (86.2-78.5) | 128 (25.2) | 56 (27.4) | Ref. | 27 (31.8) | Ref. | 3 (10.0) | Ref. | 6 (26.1) | Ref. | 20 (30.3) | Ref. |
| Q3 (78.4-77.2) | 127 (25.1) | 43 (21.1) | 0.7 (0.4-1.2) | 18 (21.2) | 0.6 (0.3-1.2) | 5 (16.7) | 1.4 (0.3-6.2) | 5 (21.7) | 0.9 (0.2-3.0) | 15 (22.7) | 0.7 (0.3-1.5) |
| Q2 (77.1-75.9) | 127 (25.1) | 60 (29.4) | 1.0 (0.7-1.6) | 21 (24.7) | 0.7 (0.4-1.4) | 10 (33.3) | 3.5 (0.9-13.1) | 9 (39.1) | 1.5 (0.5-4.5) | 20 (30.3) | 1.0 (0.5-2.1) |
| Q1 (75.8-68.1) | 125 (24.6) | 45 (22.1) | 0.8 (0.5-1.2) | 19 (22.3) | 0.6 (0.3-1.2) | 12 (40.0) | 4.4 (1.2-16.4) | 3 (13.1) | 0.5 (0.1-2.0) | 11 (16.7) | 0.5 (0.2-1.2) |
| P-trend=0.569 | P-trend=0.253 | P-trend=0.007 | P-trend=0.588 | P-trend=0.289 | |||||||
| Medianb | |||||||||||
| High (86.2-77.2) | 255 (50.3) | 99 (48.5) | Ref. | 45 (52.9) | Ref. | 8 (26.7) | Ref. | 11 (47.8) | Ref. | 35 (53.0) | Ref. |
| Low (77.1-68.1) | 252 (49.7) | 105 (51.5) | 1.1 (0.8-1.5) | 40 (47.1) | 0.9 (0.5-1.4) | 22 (73.3) | 3.2 (1.4-7.5) | 12 (52.2) | 1.1 (0.4-2.5) | 31 (47.0) | 0.9 (0.5-1.6) |
| Alu (%5mC) | |||||||||||
| Quartileb | |||||||||||
| Q4 (32.4-26.8) | 128 (24.8) | 57 (27.8) | Ref. | 23 (27.1) | Ref. | 10 (33.3) | Ref. | 5 (21.7) | Ref. | 19 (28.3) | Ref. |
| Q3 (26.7-26.1) | 130 (25.2) | 39 (19.0) | 0.7 (0.4-1.2) | 17 (20.0) | 0.8 (0.4-1.5) | 6 (20.0) | 0.6 (0.2-1.8) | 3 (13.1) | 0.7 (0.2-2.9) | 13 (19.4) | 0.7 (0.3-1.5) |
| Q2 (26.0-25.6) | 127 (24.6) | 51 (24.9) | 0.9 (0.6-1.5) | 19 (22.3) | 0.8 (0.4-1.6) | 8 (26.7) | 0.8 (0.3-2.2) | 7 (30.4) | 1.3 (0.4-4.4) | 17 (25.4) | 0.9 (0.4-1.8) |
| Q1 (25.5-23.0) | 131 (25.4) | 58 (28.3) | 1.0 (0.7-1.6) | 26 (30.6) | 1.0 (0.6-2.0) | 6 (20.0) | 0.6 (0.2-1.8) | 8 (34.8) | 1.5 (0.5-4.7) | 18 (26.9) | 1.1 (0.5-2.2) |
| P-trend=0.683 | P-trend=0.800 | P-trend=0.449 | P-trend=0.369 | P-trend=0.786 | |||||||
| Medianb | |||||||||||
| High (32.4-26.1) | 258 (50.0) | 96 (46.8) | Ref. | 40 (47.1) | Ref. | 16 (53.3) | Ref. | 8 (34.8) | Ref. | 32 (47.8) | Ref. |
| Low (26.0-23.0) | 258 (50.0) | 109 (53.2) | 1.1 (0.8-1.6) | 45 (52.9) | 1.1 (0.7-1.7) | 14 (46.7) | 0.9 (0.4-1.9) | 15 (65.2) | 1.6 (0.7-4.1) | 35 (52.2) | 1.1 (0.7-1.9) |
%5mC percentage of 5-methyl cytosine, CI confidence interval, OR odds ratio
a
Adjusted by age, BMI, race, education, smoking, pack-years, and alcohol drinking
b
The quartiles and the medians of LINE-1 or Alu measures were based on values among subjects free of baseline cancers